Evofem Biosciences amends agreement
- Amended Securities Purchase Agreement on Oct 9, 2026
- Notes payable by Dec 1, 2026
- Removed some covenants from SPA
EVFM
Evofem Biosciences, Inc. SEC filings
Every EDGAR filing for Evofem Biosciences, Inc. (EVFM), newest first, with AI summaries and stories.
- Ticker
- EVFM
- CIK
- 1618835
- Sector
- Biotech and pharma
- Latest filing
- 3d
Next: earnings expected ~Nov 16 · 10-Q expected ~Nov 16 (deadline Nov 16)
Filings
8-KEvofem Biosciences, Inc.EVFMLIVE 8-KEvofem Biosciences, Inc.EVFMLIVE 10-QEvofem Biosciences, Inc.EVFMLIVE SCHEDULE 13DEvofem Biosciences, Inc.EVFMLIVE Ownership stake disclosure by Hub Cyber Security Ltd.
Hub Cyber Security Ltd., filed by
8-KEvofem Biosciences, Inc.EVFMLIVE 8-KEvofem Biosciences, Inc.EVFMLIVE 8-KEvofem Biosciences, Inc.EVFMLIVE 10-QEvofem Biosciences, Inc.EVFMLIVE 8-KEvofem Biosciences, Inc.EVFMLIVE 8-KEvofem Biosciences, Inc.EVFMLIVE 8-KEvofem Biosciences, Inc.EVFMLIVE 8-KEvofem Biosciences, Inc.EVFMLIVE 10-KEvofem Biosciences, Inc.EVFMLIVE 8-KEvofem Biosciences, Inc.EVFMLIVE 8-KEvofem Biosciences, Inc.EVFMLIVE 8-KEvofem Biosciences, Inc.EVFMLIVE Evofem Biosciences, Inc. (EVFM) filed an 8-K report disclosing a significant leadership change. The company's CEO has stepped down, effective immediately, which could signal a strategic shift or operational challenges that investors should closely monitor.
10-QEvofem Biosciences, Inc.EVFMLIVE Evofem Biosciences, Inc. (EVFM) has filed its Q3 2025 quarterly report (Form 10-Q), providing investors with an update on the company's financial performance and operational progress.